Giang Truong Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giang Truong Ho has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Quang Huy Dương
103 Military Hospital, Vietnam Military Medical University, Hanoi, Vietnam
2 shared publications - Thuy Thi Bich Vo
Institute of Biology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Nghia Do, Hanoi 100000, Vietnam
2 shared publications - Diem Thi Nguyen
Institute of Biology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Nghia Do, Hanoi 100000, Vietnam
1 shared publication - Khai Xuan Nguyen
103 Military Hospital, Vietnam Military Medical University, Hanoi 100000, Vietnam
1 shared publication - Minh Ngoc Nghiem
Institute of Genome Research, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
1 shared publication
Latest Publications
- 2 January 2025
- Published by Learning Gate in Edelweiss Applied Science and Technology
- Vol. 9 (1) , 1010-1018
Evaluation of the sensitivity and specificity of monoclonal antibodies for detecting the thioredoxin antigen in hepatocellular carcinoma patients
The objective of this study was to evaluate the sensitivity and specificity of the monoclonal antibody of thioredoxin (mAb-TXN) for detecting the thioredoxin (TXN) antigen in serum samples from patients with hepatocellular carcinoma (HCC). To achieve this, the mAb-TXN, generated from hybridoma cells, was utilized to optimize the conditions for an indirect ELISA immunoassay. The sensitivity, specificity, positive predictive value, and negative predictive value of the assay were evaluated on the basis of stored patient medical records. The results showed that indirect ELISA using mAb-TXN exhibited a sensitivity of 93.61%, a specificity of 96%, a positive predictive value of 97.77%, and a negative predictive value of 88%. In conclusion, mAb-TXN is a valuable tool for detecting TXN antigens in serum samples from HCC patients, offering high sensitivity and specificity for clinical application.
- 2 January 2025
- Published by Learning Gate in Edelweiss Applied Science and Technology
- Vol. 9 (1) , 1010-1018
Evaluation of the sensitivity and specificity of monoclonal antibodies for detecting the thioredoxin antigen in hepatocellular carcinoma patients
The objective of this study was to evaluate the sensitivity and specificity of the monoclonal antibody of thioredoxin (mAb-TXN) for detecting the thioredoxin (TXN) antigen in serum samples from patients with hepatocellular carcinoma (HCC). To achieve this, the mAb-TXN, generated from hybridoma cells, was utilized to optimize the conditions for an indirect ELISA immunoassay. The sensitivity, specificity, positive predictive value, and negative predictive value of the assay were evaluated on the basis of stored patient medical records. The results showed that indirect ELISA using mAb-TXN exhibited a sensitivity of 93.61%, a specificity of 96%, a positive predictive value of 97.77%, and a negative predictive value of 88%. In conclusion, mAb-TXN is a valuable tool for detecting TXN antigens in serum samples from HCC patients, offering high sensitivity and specificity for clinical application.
- Open Access
- 7 August 2024
- Published by Asian Economic and Social Society in Journal of Asian Scientific Research
- Vol. 14 (4) , 586-596
Development of an indirect ELISA to detect antigens using DNA origami nanoantenna labeled specific monoclonal antibodies
This research examines the development of an indirect ELISA to detect antigens using DNA origami nanoantenna-labeled specific monoclonal antibodies. Hepatocellular carcinoma (HCC) is one of the five most common cancers and the second leading cause of cancer-related death worldwide. More than 60% of cases are detected in the late stage, with the absence of specific symptoms in the early stage of the disease. Adding measurements of AFP (Alpha-Fetoprotein), TXN (Thioredoxin), and DCP (Des-γ-Carboxy Prothrombin) has the potential to improve the accuracy of diagnosing hepatocellular carcinoma. DNA origami technology is revolutionizing the forefront of cancer diagnostics, particularly for HCC. In this study, an indirect enzyme-linked immunosorbent assay (ELISA) method targeting the assessment of the effectiveness of specific monoclonal antibody-conjugated DNA origami particles was developed. The results of DNA origami folding into complex nanostructures and labeled biomarkers like AFP, DCP, and TXN have explored the high specificity and sensitivity for targeting HCC. We found the cut-off values for AFP, DCP, and TXN to be 0.132, 0.156, and 0.150, respectively. The coefficients of variation for samples remained consistently under 10%, indicating the method's high degree of stability and reproducibility. This innovation, combined with biomarkers, promised in early HCC detection, holds the potential to significantly enhance patient outcomes in the fight against liver cancer. The platform also has enormous potential for advancing personalized medicine.
- 7 August 2024
- Published by Asian Economic and Social Society in Journal of Asian Scientific Research
- Vol. 14 (4) , 586-596
Open AccessDevelopment of an indirect ELISA to detect antigens using DNA origami nanoantenna labeled specific monoclonal antibodies
This research examines the development of an indirect ELISA to detect antigens using DNA origami nanoantenna-labeled specific monoclonal antibodies. Hepatocellular carcinoma (HCC) is one of the five most common cancers and the second leading cause of cancer-related death worldwide. More than 60% of cases are detected in the late stage, with the absence of specific symptoms in the early stage of the disease. Adding measurements of AFP (Alpha-Fetoprotein), TXN (Thioredoxin), and DCP (Des-γ-Carboxy Prothrombin) has the potential to improve the accuracy of diagnosing hepatocellular carcinoma. DNA origami technology is revolutionizing the forefront of cancer diagnostics, particularly for HCC. In this study, an indirect enzyme-linked immunosorbent assay (ELISA) method targeting the assessment of the effectiveness of specific monoclonal antibody-conjugated DNA origami particles was developed. The results of DNA origami folding into complex nanostructures and labeled biomarkers like AFP, DCP, and TXN have explored the high specificity and sensitivity for targeting HCC. We found the cut-off values for AFP, DCP, and TXN to be 0.132, 0.156, and 0.150, respectively. The coefficients of variation for samples remained consistently under 10%, indicating the method's high degree of stability and reproducibility. This innovation, combined with biomarkers, promised in early HCC detection, holds the potential to significantly enhance patient outcomes in the fight against liver cancer. The platform also has enormous potential for advancing personalized medicine.